Journal profile · Oncology
Journal of Experimental & Clinical Cancer Research
ISSN 1756-9966 · BioMed Central · ITALY · Quarterly · Founded 2008
Journal of Experimental & Clinical Cancer Research: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 14.28; fully open access; APC about USD 4,490; median 103 days to acceptance (92 articles, last 24 months); community-reported acceptance: about 66.66%; 361 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Experimental & Clinical Cancer Research is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer-related molecular mechanisms research, MicroRNA in disease regulation and Cancer Cells and Metastasis, together about 23.9% of its articles. Its main subfields are Cancer Research and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that publishes original research papers, reviews and commentaries in cancer research, from bench to bedside. Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer. Specific areas of interest include, but are not limited to: mechanisms of progression of the malignant phenotype and metastatic disease; molecular alterations or biomarkers that predict response or resistance to treatment; translational research in targeted therapies; personalized medicine; tumor immunotherapy; large-scale molecular characterization of human tumors and innovative methods with potential applicability to clinical investigation. The following criteria provide an overview of the types of studies considered by the journal: Findings that have not been previously published in the same tumor model. Studies performed in multiple cell lines. Conclusions that are not representative of incremental findings. Studies that include a clearly written title and abstract that communicate the study's impact of significance to non-experts. The online appearance of Journal of Experimental & Clinical Cancer Research allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community. Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that publishes original research papers, reviews and commentaries in cancer research, from bench to bedside. Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer. Specific areas of interest include, but are not limited to: mechanisms of progression of the malignant phenotype and metastatic disease; molecular alterations or biomarkers that predict response or resistance to treatment; translational research in targeted therapies; personalized medicine; tumor immunotherapy; large-scale molecular characterization of human tumo
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Mauro CastelliPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named Italy 27, United States 11, Germany 3, United Kingdom 2, France 2 (58 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology8.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology7.9%
- Cancer Cells and MetastasisMedicine7.3%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology6.9%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology6.9%
- Ferroptosis and cancer prognosisMedicine5.2%
- Immune cells in cancerImmunology and Microbiology5.2%
- Cancer Immunotherapy and BiomarkersMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.28LetPub ·
- Impact factor (publisher) 2025
- 14.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 14.3Publisher website ·
- CiteScore 2026-06
- 22.3LetPub ·
- SJR 2026-06
- 3.73LetPub ·
- SNIP 2026-06
- 2.27LetPub ·
- h-index
- 67LetPub ·
- h-index
- 186OpenAlex ·
- i10-index
- 3,650OpenAlex ·
- 2-year mean citedness
- 12.97OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 99.89%LetPub ·
Volume
- Articles per year
- 317LetPub ·
- Downloads per year (publisher) 2025
- 5,900,000Publisher website ·
Articles by year OpenAlex count · 4,671 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 213 | 213 | 175 |
| 2025 | 361 | 361 | 3,903 |
| 2024 | 335 | 335 | 7,714 |
| 2023 | 347 | 347 | 11,939 |
| 2022 | 365 | 365 | 20,350 |
| 2021 | 404 | 404 | 24,780 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
103 daysMedian, submission to acceptance · P25–P75 76 days – 130 days
- Acceptance to online
- median 14 days (92 articles)
- Submission to online
- median 121 days
- Sample
- 92 articles with submission and acceptance dates (641 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 66.66%LetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,790 / USD 4,490 / GBP 3,190 | Yes | CC BY, CC0 | |
| OpenAlex | USD 4,190 / EUR 3,490 / GBP 2,990 | — | — | |
| LetPub | GBP 2,890 / USD 3,990 / EUR 3,390 | Yes | — | |
| Publisher website | GBP 3,190 / USD 4,490 / EUR 3,790 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare1 items from the author guidelines
- Suggested reviewers
- Optional
Article types accepted4
- commentaryResearch articles Review Commentary Meeting reportLength not stated
- meeting reportResearch articles Review Commentary Meeting reportLength not stated
- research articlesResearch articles Review Commentary Meeting reportLength not stated
- reviewResearch articles Review Commentary Meeting reportLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing strongly encouraged or required; deposit in public repositories where appropriate. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access under CC BY 4.0; CC0 data policy. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Journal of Experimental & Clinical Cancer Research articles are published open access under a CC BY (Creativ…
Source ↗Publisher website ·- Open access Benefits of open access
APC waivers for low-income countries; discretionary waivers case-by-case at submission. Model summary
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ITALY
- Language
- English
- Frequency
- Quarterly
- Founded
- 2008
- ISSN
- 1756-9966
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Experimental & Clinical Cancer Research
What CAS zone is Journal of Experimental & Clinical Cancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Experimental & Clinical Cancer Research is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Experimental & Clinical Cancer Research?
The latest impact factor listed by LetPub is 14.28; CiteScore 22.3, h-index 186.
How long does peer review take at Journal of Experimental & Clinical Cancer Research?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 103 days (interquartile range 76–130 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 66.66%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Experimental & Clinical Cancer Research based?
Of the 58 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are Italy (27), United States (11) and Germany (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Experimental & Clinical Cancer Research?
According to LetPub and DOAJ records, Journal of Experimental & Clinical Cancer Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Journal of Experimental & Clinical Cancer Research open access, and what is the APC?
Journal of Experimental & Clinical Cancer Research is a fully open-access journal. APC about USD 4,490.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .